$HYEX
HEALTHY EXTRACTS INC. Stock $hyex

$hyex Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000109690623001093 Filed on May 15, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$588.5K	$614.9K	$463.4K
YoY Change	25.26%	32.71%	171.89%
Cost Of Revenue	$303.4K	$337.1K	$138.7K
YoY Change	55.16%	143.08%	234.65%
Gross Profit	$285.1K	$277.8K	$324.7K
YoY Change	3.94%	-14.43%	151.73%
Gross Profit Margin	48.44%	45.18%	70.07%
Selling, General & Admin	$1.541M	$683.0K	$370.4K
YoY Change	60.34%	84.42%	-48.28%
% of Gross Profit	540.55%	245.83%	114.06%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$550.00	$550.00
YoY Change
% of Gross Profit	0.19%	0.2%
Operating Expenses	$1.541M	$683.0K	$370.4K
YoY Change	73.45%	84.42%	-48.28%
Operating Profit	-$1.256M	-$405.2K	-$45.65K
YoY Change	104.49%	787.6%	-92.22%
Interest Expense	-$11.36K	-$174.0K	$46.02K
YoY Change	-95.37%	-478.03%	-106.51%
% of Operating Profit
Other Income/Expense, Net	-$11.36K	-$174.0K	$48.66K
YoY Change	-95.37%	-457.49%
Pretax Income	-$1.267M	-$579.2K	$3.010K
YoY Change	47.47%	-19341.2%	-100.23%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$1.267M	-$579.2K	$3.010K
YoY Change	47.47%	-19341.1%	-100.23%
Net Earnings / Revenue	-215.34%	-94.18%	0.65%
Basic Earnings Per Share
Diluted Earnings Per Share	$0.00	$0.00	$9.59
COMMON SHARES
Basic Shares Outstanding	345.2M shares	345.2M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$92.50K	$213.2K	$92.29K
YoY Change	-41.97%	131.01%	-60.38%
Cash & Equivalents	$92.50K	$213.2K	$92.29K
Short-Term Investments
Other Short-Term Assets	$219.3K
YoY Change
Inventory	$1.465M	$1.654M	$2.009M
Prepaid Expenses
Receivables	$114.9K	$135.4K	$109.2K
Other Receivables	$34.50K	$0.00	$0.00
Total Short-Term Assets	$1.925M	$2.003M	$2.210M
YoY Change	-9.56%	-9.37%	-19.26%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.400K	$4.950K	$7.150K
YoY Change	-33.33%	-30.77%	47.12%
Goodwill	$193.3K	$193.3K
YoY Change	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$16.89K	$102.5K	$16.89K
YoY Change	0.0%	506.99%
Total Long-Term Assets	$737.0K	$822.6K	$739.2K
YoY Change	-0.22%	11.29%	11.68%
TOTAL ASSETS
Total Short-Term Assets	$1.925M	$2.003M	$2.210M
Total Long-Term Assets	$737.0K	$822.6K	$739.2K
Total Assets	$2.662M	$2.825M	$2.949M
YoY Change	-7.15%	-4.2%	-13.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$112.3K	$114.5K	$105.4K
YoY Change	-1.59%	8.6%	113.27%
Accrued Expenses	$28.67K	$85.87K	$27.24K
YoY Change	268.35%	215.24%	-59.35%
Deferred Revenue
YoY Change
Short-Term Debt	$1.024M	$1.084M	$357.6K
YoY Change	101.47%	203.1%	-30.91%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.481M	$1.510M	$503.8K
YoY Change	65.3%	199.75%	-62.18%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$47.41K
YoY Change
Total Long-Term Liabilities	$47.41K	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.481M	$1.510M	$503.8K
Total Long-Term Liabilities	$47.41K	$0.00	$0.00
Total Liabilities	$1.481M	$1.510M	$503.8K
YoY Change	65.3%	199.75%	-62.18%
SHAREHOLDERS EQUITY
Retained Earnings	-$17.77M	-$16.51M
YoY Change	12.49%
Common Stock	$345.5K	$345.5K
YoY Change	0.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.181M	$1.315M	$2.445M
YoY Change
Total Liabilities & Shareholders Equity	$2.662M	$2.825M	$2.949M
YoY Change	-7.15%	-4.2%	-13.24%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$1.267M	-$579.2K	$3.010K
YoY Change	47.47%	-19341.1%	-100.23%
Depreciation, Depletion And Amortization	$550.00	$550.00
YoY Change
Cash From Operating Activities	-$93.23K	-$310.3K	-$108.4K
YoY Change	101.49%	186.19%	-82.93%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$7.990K
YoY Change		-100.0%	-0.62%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities	$0.00	$0.00	-$7.990K
YoY Change		-100.0%	-78.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			-$28.42K
YoY Change			-105.61%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-27.47K	$457.8K	-13.42K
YoY Change	-124.23%	-3511.42%	-101.58%
NET CHANGE
Cash From Operating Activities	-93.23K	-$310.3K	-108.4K
Cash From Investing Activities	0.000	$0.00	-7.990K
Cash From Financing Activities	-27.47K	$457.8K	-13.42K
Net Change In Cash	-120.7K	$147.6K	-129.8K
YoY Change	-279.83%	-213.66%	-174.73%
FREE CASH FLOW
Cash From Operating Activities	-$93.23K	-$310.3K	-$108.4K
Capital Expenditures	$0.00	$0.00	-$7.990K
Free Cash Flow	-$93.23K	-$310.3K	-$100.4K
YoY Change	101.49%	208.96%	-83.99%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	000-55572
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Healthy Extracts Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-2594704
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	7375 Commercial Way
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 125
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Henderson
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NV
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	89011
CY2023Q1	dei	City Area Code CityAreaCode	702
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	463-1004
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	345172442	shares
CY2023Q1	us-gaap	Cash Cash	213204	usd
CY2022Q4	us-gaap	Cash Cash	65651	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	135398	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	105794	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	1654206	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1819128	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	2002808	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1990572	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	44709	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	45474	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	4952	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	5501	usd
CY2023Q1	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	521881	usd
CY2022Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	521881	usd
CY2023Q1	us-gaap	Deposits Assets DepositsAssets	16890	usd
CY2022Q4	us-gaap	Deposits Assets DepositsAssets	16890	usd
CY2023Q1	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	85632	usd
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	53015	usd
CY2023Q1	us-gaap	Goodwill Goodwill	193260	usd
CY2022Q4	us-gaap	Goodwill Goodwill	193260	usd
CY2023Q1	us-gaap	Other Assets OtherAssets	822614	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	790546	usd
CY2023Q1	us-gaap	Assets Assets	2825422	usd
CY2022Q4	us-gaap	Assets Assets	2781118	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	114485	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	91316	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	85871	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	94554	usd
CY2023Q1	us-gaap	Notes Payable Current NotesPayableCurrent	487445	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	275370	usd
CY2023Q1	fil	Notes Payable Related Party NotesPayableRelatedParty	866	usd
CY2022Q4	fil	Notes Payable Related Party NotesPayableRelatedParty	866	usd
CY2023Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	595638	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	317284	usd
CY2023Q1	fil	Convertible Debt Related Party Net Of Discount ConvertibleDebtRelatedPartyNetOfDiscount	0	usd
CY2022Q4	fil	Convertible Debt Related Party Net Of Discount ConvertibleDebtRelatedPartyNetOfDiscount	0	usd
CY2023Q1	us-gaap	Interest Payable Current InterestPayableCurrent	39023	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	21387	usd
CY2023Q1	fil	Accrued Interest Payable Related Party AccruedInterestPayableRelatedParty	0	usd
CY2022Q4	fil	Accrued Interest Payable Related Party AccruedInterestPayableRelatedParty	0	usd
CY2023Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	186919	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	102011	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1510248	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	902788	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	75000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	75000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2500000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	345492442	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	345492442	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	345172442	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	345172442	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	345492	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	345172	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	17475579	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	17459899	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-16505898	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15926742	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	1315174	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1878330	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2825422	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2781118	usd
CY2023Q1	us-gaap	Sales Type Lease Revenue SalesTypeLeaseRevenue	614943	usd
CY2022Q1	us-gaap	Sales Type Lease Revenue SalesTypeLeaseRevenue	551654	usd
CY2023Q1	us-gaap	Revenues Revenues	614943	usd
CY2022Q1	us-gaap	Revenues Revenues	551654	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	320724	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	226949	usd
CY2023Q1	us-gaap	Inventory Write Down InventoryWriteDown	16378	usd
CY2022Q1	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	337102	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	226949	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	277841	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	324705	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	683029	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	370357	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	683029	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	370357	usd
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-89060	usd
CY2022Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-32957	usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-84908	usd
CY2022Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	78978	usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023Q1	fil	Sba Loan Forgiveness SbaLoanForgiveness	0	usd
CY2022Q1	fil	Sba Loan Forgiveness SbaLoanForgiveness	0	usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	0	usd
CY2022Q1	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	2643	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-173968	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	48664	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-579157	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	3011	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-579157	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	3011	usd
CY2023Q1	fil	Loss Per Share Basic And Diluted LossPerShareBasicAndDiluted	-0.00
CY2022Q1	fil	Loss Per Share Basic And Diluted LossPerShareBasicAndDiluted	0.00
CY2023Q1	fil	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	342514810	shares
CY2022Q1	fil	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	313764817	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	2470738	usd
CY2022	fil	Cancelation Of Common Stock For Debt CancelationOfCommonStockForDebt	-10013	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	25396	usd
CY2022	fil	Cancelation Of Common Stock For Debt1 CancelationOfCommonStockForDebt1	-43800	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	64000	usd
CY2022	fil	Stock Issued During Period Value Issued For Services2 StockIssuedDuringPeriodValueIssuedForServices2	57100	usd
CY2022	fil	Stock Issued During Period Value Issued For Services3 StockIssuedDuringPeriodValueIssuedForServices3	264000	usd
CY2022	fil	Issuance Of Common Stock Note Conversion IssuanceOfCommonStockNoteConversion	17031	usd
CY2022	fil	Stock Issued During Period Value Issued For Services4 StockIssuedDuringPeriodValueIssuedForServices4	17000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-983121	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1878330	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	16000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-579157	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	1315174	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-579157	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	3011	usd
CY2023Q1	fil	Depreciation And Amortization1 DepreciationAndAmortization1	549	usd
CY2022Q1	fil	Depreciation And Amortization1 DepreciationAndAmortization1	-768	usd
CY2023Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	16000	usd
CY2022Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	0	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	0	usd
CY2023Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	84908	usd
CY2022Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-78978	usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023Q1	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	0	usd
CY2022Q1	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	-2643	usd
CY2023Q1	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
CY2022Q1	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	29604	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-24169	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-164922	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	50558	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	0	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	0	usd
CY2023Q1	us-gaap	Increase Decrease In Deposits IncreaseDecreaseInDeposits	0	usd
CY2022Q1	us-gaap	Increase Decrease In Deposits IncreaseDecreaseInDeposits	-16890	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	23170	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	68153	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	0	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	0	usd
CY2023Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-8683	usd
CY2022Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-54767	usd
CY2023Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	17636	usd
CY2022Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-7822	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	0	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3400	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-310259	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-108408	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7987	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2022Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2023Q1	fil	Purchase Of Note Receivable PurchaseOfNoteReceivable	0	usd
CY2022Q1	fil	Purchase Of Note Receivable PurchaseOfNoteReceivable	0	usd
CY2023Q1	fil	Increase Decrease In Trademarks IncreaseDecreaseInTrademarks	0	usd
CY2022Q1	fil	Increase Decrease In Trademarks IncreaseDecreaseInTrademarks	0	usd
CY2023Q1	us-gaap	Repayment Of Notes Receivable From Related Parties RepaymentOfNotesReceivableFromRelatedParties	0	usd
CY2022Q1	us-gaap	Repayment Of Notes Receivable From Related Parties RepaymentOfNotesReceivableFromRelatedParties	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7987	usd
CY2023Q1	fil	Purchase Of Hyperion Op M PurchaseOfHyperionOpM	-32617	usd
CY2022Q1	fil	Purchase Of Hyperion Op M PurchaseOfHyperionOpM	0	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	-28417	usd
CY2023Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	167819	usd
CY2022Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	202000	usd
CY2023Q1	fil	Payments For Repayment Of Convertible Debt PaymentsForRepaymentOfConvertibleDebt	-110535	usd
CY2022Q1	fil	Payments For Repayment Of Convertible Debt PaymentsForRepaymentOfConvertibleDebt	167000	usd
CY2023Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	136705	usd
CY2022Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
CY2023Q1	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	75370	usd
CY2022Q1	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	0	usd
CY2023Q1	fil	Proceeds From Issuance Of Notes Payable Related Party ProceedsFromIssuanceOfNotesPayableRelatedParty	0	usd
CY2022Q1	fil	Proceeds From Issuance Of Notes Payable Related Party ProceedsFromIssuanceOfNotesPayableRelatedParty	-20000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	457812	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-13417	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	147553	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-129812	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	65651	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	222098	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	213204	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	92286	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"><b><i>Use of Estimates</i></b></p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">In regards to inventory write-offs and allowances, our Company policy is to review all expiration dates for all our products, at a minimum quarterly. If a product is within twelve months of expiration we will discuss if this amount of product will be sold within those months. If we have a surplus of product over the twelve month demand, we will write-off the additional amount during the current reporting period. If we have any damaged or unsellable inventory items, we will automatically write-off those items in the current month report period.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">As for revenue adjustments for discounts, allowances and refunds, we treat each of these items differently. When it comes to revenue discounts, we will create the invoice for the product sold which will include any discounts given. These discounts usually happen for a short period of time for sales that we will offer around holidays. Due to the revenue being recognized once the order has shipped, less any applicable discount, we book this transaction at the net order transaction amount. In regards to allowances and refunds for revenue adjustments, due to our refund percentage is less than 1% we decided the need for an estimated adjustment for allowances and refunds was not material. If we do receive any returned orders, we will directly book those orders as refunds the day we receive the call from the customer requesting the refund. We will book the credit memo at the full value of the customer original order.</p>
CY2023Q1	fil	Inventory Allowances InventoryAllowances	1914891	usd
CY2022Q1	fil	Inventory Allowances InventoryAllowances	1914891	usd
CY2023Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	1313407	usd
CY2022Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	1571458	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	317493	usd
CY2022Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	330848	usd
CY2023Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	23306	usd
CY2022Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	106218	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	1654206	usd
CY2022Q1	us-gaap	Inventory Net InventoryNet	2008524	usd
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"><b><i>Concentration</i></b></p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">There is no concentration of revenue for the months ended March 31, 2022 and for the months ended March 31, 2023 because the revenue was earned from multiple customers.</p>
CY2023Q1	fil	Operating Loss Carryforwards Running Total OperatingLossCarryforwardsRunningTotal	-16505899	usd
CY2023Q1	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	3005237	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	2883614	usd
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	2677158	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	102011	usd
CY2023Q1	fil	Convertible Debt Issued ConvertibleDebtIssued	133031	usd
CY2023Q1	fil	Convertible Debt Change In Fair Value Recognized In Operations ConvertibleDebtChangeInFairValueRecognizedInOperations	-48123	usd
CY2023Q1	fil	Convertible Debt Converted ConvertibleDebtConverted	0	usd
CY2023Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	186919	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-16505898	usd
CY2023Q1	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	0	usd
CY2022Q1	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	1000	usd
CY2023Q1	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	51169	usd
CY2023Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	70883	usd
CY2023Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	5926	usd
CY2023Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	144851	usd
CY2023Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	16873	usd
CY2022Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	15370	usd
CY2023Q1	fil	Due To Related Parties1 DueToRelatedParties1	330866	usd
CY2023Q1	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	14214	usd
CY2023Q1	us-gaap	Convertible Debt ConvertibleDebt	595638	usd
CY2023Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	0	usd
CY2023Q1	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	595638	usd
CY2023Q1	fil	Convertible Debt Accrued Interest ConvertibleDebtAccruedInterest	21200	usd
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	75000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	75000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	75000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2500000000	shares
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2500000000	shares
CY2023Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	The Company effectuated a reverse stock split of 1-for-250 as of July 23, 2018
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	fil	Warrants Issued WarrantsIssued	7421544	shares
CY2023Q1	fil	Warrants Outstanding WarrantsOutstanding	23421544	shares
CY2023Q1	fil	Warrants Fully Vested WarrantsFullyVested	20600000	shares
CY2022Q1	fil	Issuance Of Common Stock Omnibus Stock Grant And Option Plan IssuanceOfCommonStockOmnibusStockGrantAndOptionPlan	7500000	shares

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
hyex-20230331_cal.xml	Edgar Link	unprocessable
0001096906-23-001093-index-headers.html	Edgar Link	pending
0001096906-23-001093-index.html	Edgar Link	pending
0001096906-23-001093.txt	Edgar Link	pending
0001096906-23-001093-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
hyex-20230331.htm	Edgar Link	pending
hyex-20230331.xsd	Edgar Link	pending
hyex10q_1.jpg	Edgar Link	pending
hyex_ex31z1.htm	Edgar Link	pending
hyex_ex31z2.htm	Edgar Link	pending
hyex_ex32z1.htm	Edgar Link	pending
hyex_ex32z2.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
hyex-20230331_def.xml	Edgar Link	unprocessable
hyex-20230331_lab.xml	Edgar Link	unprocessable
hyex-20230331_pre.xml	Edgar Link	unprocessable
hyex-20230331_htm.xml	Edgar Link	completed
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HYEX
HEALTHY EXTRACTS INC. Stock $hyex

2023 Q2 Form 10-Q Financial Statement

#000109690623001093 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HYEX HEALTHY EXTRACTS INC. Stock $hyex

2023 Q2 Form 10-Q Financial Statement

#000109690623001093 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HYEX
HEALTHY EXTRACTS INC. Stock $hyex